Evobrutinib: Difference between revisions

Browse history interactively ← Previous editContent deleted Content addedVisual WikitextInline

Revision as of 07:59, 26 December 2024 editGraeme Bartlett (talk \| contribs)Administrators250,058 edits added Category:Piperidines using HotCat ← Previous edit		Latest revision as of 08:01, 26 December 2024 edit undoCitation bot (talk \| contribs)Bots5,450,103 edits Altered issue. Formatted dashes. \| Use this bot. Report bugs. \| Suggested by Graeme Bartlett \| #UCB_toolbar
(One intermediate revision by one other user not shown)
Line 79:		Line 79:
	\| IUPHAR_ligand =		\| IUPHAR_ligand =
	\| DrugBank = DB15170		\| DrugBank = DB15170
	\| ChemSpiderID =		\| ChemSpiderID = 58827807
	\| UNII = ZA45457L1K		\| UNII = ZA45457L1K
	\| KEGG = D12467		\| KEGG = D12467
Line 109:		Line 109:
	}}		}}

	'''Evobrutinib''' is an experimental drug being studied for the treatment of ] and ].<ref>{{cite web \| url = https://adisinsight.springer.com/drugs/800041955 \| title = Evobrutinib \| work = AdisInsight \| publisher = Springer Nature Switzerland AG }}</ref><ref>{{cite journal \| vauthors = Montalban X, Piasecka-Stryczynska K, Kuhle J, Benkert P, Arnold DL, Weber MS, Seitzinger A, Guehring H, Shaw J, Tomic D, Hyvert Y, Harlow DE, Dyroff M, Wolinsky JS \| title = Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study \| journal = Multiple Sclerosis \| volume = 30 \| issue = ~~4-5~~ \| pages = 558–570 \| date = April 2024 \| pmid = 38436271 \| pmc = 11080380 \| doi = 10.1177/13524585241234783 }}</ref><ref>{{cite journal \| vauthors = Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BA, Cross AH, Kubala Havrdova E, Kappos L, Stuve O, Wiendl H, Wolinsky JS, Dahlke F, Le Bolay C, Shen Loo L, Gopalakrishnan S, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D \| title = Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials \| journal = The Lancet. Neurology \| volume = 23 \| issue = 11 \| pages = 1119–1132 \| date = November 2024 \| pmid = 39307151 \| doi = 10.1016/S1474-4422(24)00328-4 }}</ref> It is an ] of ].<ref>{{cite web \| url = https://mstrust.org.uk/a-z/evobrutinib \| title = Evobrutinib \| publisher = Multiple Sclerosis Trust }}</ref>		'''Evobrutinib''' is an experimental drug being studied for the treatment of ] and ].<ref>{{cite web \| url = https://adisinsight.springer.com/drugs/800041955 \| title = Evobrutinib \| work = AdisInsight \| publisher = Springer Nature Switzerland AG }}</ref><ref>{{cite journal \| vauthors = Montalban X, Piasecka-Stryczynska K, Kuhle J, Benkert P, Arnold DL, Weber MS, Seitzinger A, Guehring H, Shaw J, Tomic D, Hyvert Y, Harlow DE, Dyroff M, Wolinsky JS \| title = Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study \| journal = Multiple Sclerosis \| volume = 30 \| issue = 4–5 \| pages = 558–570 \| date = April 2024 \| pmid = 38436271 \| pmc = 11080380 \| doi = 10.1177/13524585241234783 }}</ref><ref>{{cite journal \| vauthors = Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BA, Cross AH, Kubala Havrdova E, Kappos L, Stuve O, Wiendl H, Wolinsky JS, Dahlke F, Le Bolay C, Shen Loo L, Gopalakrishnan S, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D \| title = Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials \| journal = The Lancet. Neurology \| volume = 23 \| issue = 11 \| pages = 1119–1132 \| date = November 2024 \| pmid = 39307151 \| doi = 10.1016/S1474-4422(24)00328-4 }}</ref> It is an ] of ].<ref>{{cite web \| url = https://mstrust.org.uk/a-z/evobrutinib \| title = Evobrutinib \| publisher = Multiple Sclerosis Trust }}</ref>

	==References==		==References==

Latest revision as of 08:01, 26 December 2024

Pharmaceutical compound

Evobrutinib
Legal status

Legal status	Investigational
Identifiers
IUPAC name 1-amino]methyl]piperidin-1-yl]prop-2-en-1-one
CAS Number	1415823-73-2
PubChem CID	71479709
DrugBank	DB15170
ChemSpider	58827807
UNII	ZA45457L1K
KEGG	D12467
ChEMBL	ChEMBL4072833
Chemical and physical data
Formula	C₂₅H₂₇N₅O₂
Molar mass	429.524 g·mol
3D model (JSmol)	Interactive image
SMILES C=CC(=O)N1CCC(CC1)CNC2=NC=NC(=C2C3=CC=C(C=C3)OC4=CC=CC=C4)N
InChI InChI=InChI=1S/C25H27N5O2/c1-2-22(31)30-14-12-18(13-15-30)16-27-25-23(24(26)28-17-29-25)19-8-10-21(11-9-19)32-20-6-4-3-5-7-20/h2-11,17-18H,1,12-16H2,(H3,26,27,28,29) Key:QUIWHXQETADMGN-UHFFFAOYSA-N

Evobrutinib is an experimental drug being studied for the treatment of encephalomyelitis and multiple sclerosis. It is an inhibitor of Bruton's tyrosine kinase.

References

"Evobrutinib". AdisInsight. Springer Nature Switzerland AG.
Montalban X, Piasecka-Stryczynska K, Kuhle J, Benkert P, Arnold DL, Weber MS, et al. (April 2024). "Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study". Multiple Sclerosis. 30 (4–5): 558–570. doi:10.1177/13524585241234783. PMC 11080380. PMID 38436271.
Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BA, Cross AH, et al. (November 2024). "Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials". The Lancet. Neurology. 23 (11): 1119–1132. doi:10.1016/S1474-4422(24)00328-4. PMID 39307151.
"Evobrutinib". Multiple Sclerosis Trust.

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

Categories: